Advertisement

From Oncologist’s Desk: Hemato-Oncological Aspect of Using Vaporizers, E-Cigarettes, and Other Electronic Nicotine Delivery Systems (ENDS)

  • Kamal Kant SahuEmail author
  • Ajay Kumar Mishra
  • Amos Lal
  • Ahmad Daniyal Siddiqui
  • George M. Abraham
Correspondence
  • 5 Downloads

Dear Editor,

Electronic nicotine delivery systems (ENDS) like E-cigarettes are the smokeless and non-combustible alternative to conventional cigarette smoking, and have become increasingly popular in recent times. Since the time they came into existence, they have been surrounded by many controversies related to their ill-impact on health and wellbeing. On one side, youth today in increased numbers are engaging themselves with vaporizers and E-cigarettes in an attempt to either quit smoking or to have naïve experience, but at the same time the long-term effects of using these ENDS are yet to be known. Through this letter, we aim to raise our concern on the ill effects of E-cigarettes with special emphasis on their impact on hematological/oncological system.

As per Food and Drug Administration (FDA), United States (US) approximately there is 480,000 deaths per year in the U.S. alone from tobacco-associated cancers, emphysema, heart disease and stroke. Hence, every attempt should be made...

Notes

Funding

None.

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical Statement

The article doesn’t contain participation of any human being and animal.

References

  1. 1.
    Zhu SH, Sun JY, Bonnevie E, Cummins SE, Gamst A, Yin L et al (2014) Four hundred and sixty brands of e-cigarettes and counting: implications for product regulation. Tob Control 23(Suppl. 3):iii3–iii9CrossRefGoogle Scholar
  2. 2.
    Maessen GC, Wijnhoven AM, Neijzen RL, Paulus MC, van Heel DAM, Bomers BHA, Boersma LE, Konya B, van der Heyden MAG (2019) Nicotine intoxication by e-cigarette liquids: a study of case reports and pathophysiology. Clin Toxicol (Phila) 9:1–8CrossRefGoogle Scholar
  3. 3.
    Kaur G, Muthumalage T, Rahman I (2018) Mechanisms of toxicity and biomarkers of flavoring and flavor enhancing chemicals in emerging tobacco and non-tobacco products. Toxicol Lett 15(288):143–155CrossRefGoogle Scholar
  4. 4.
    Muthumalage T, Prinz M, Ansah KO, Gerloff J, Sundar IK, Rahman I (2018) Inflammatory and oxidative responses induced by exposure to commonly used E-cigarette flavoring chemicals and flavored e-liquids without nicotine. Front Physiol 8:1130CrossRefGoogle Scholar
  5. 5.
    Khan MS, Khateeb F, Akhtar J, Khan Z, Lal A, Kholodovych V, Hammersley J (2018) Organizing pneumonia related to electronic cigarette use: a case report and review of literature. Clin Respir J 12(3):1295–1299CrossRefGoogle Scholar
  6. 6.
    Morgan DL, Jokinen MP, Price HC, Gwinn WM, Palmer SM, Flake GP (2012) Bronchial and bronchiolar fibrosis in rats exposed to 2,3-pentanedione vapors: implications for bronchiolitis obliterans in humans. Toxicol Pathol 40(3):448–465CrossRefGoogle Scholar
  7. 7.
    Flach S, Maniam P, Manickavasagam J (2019) E-cigarettes and head and neck cancers: a systematic review of the current literature. Clin Otolaryngol 44(5):749–756Google Scholar
  8. 8.
    McConnell DD, Carr SB, Litofsky NS (2019) Potential effects of nicotine on glioblastoma and chemoradiotherapy: a review. Expert Rev Neurother 19(6):545–555CrossRefGoogle Scholar
  9. 9.
    Twohig P, Rivington J, Cook W (2019) Are E-cigarettes the answer? A novel case of methemoglobinemia. Am J Med.  https://doi.org/10.1016/j.amjmed.2019.02.051
  10. 10.
    Sahu KK, Lal A, Kumar Mishra A, Sahu SA (2019) E-Cigarettes and methemoglobinemia: a Wolf in sheep’s clothing. Am J Med.  https://doi.org/10.1016/j.amjmed.2019.06.009
  11. 11.
    Jankowski M, Krzystanek M, Zejda JE, Majek P, Lubanski J, Lawson JA, Brozek G (2019) E-cigarettes are more addictive than traditional cigarettes—a study in highly educated young people. Int J Environ Res Public Health 16(13):2279CrossRefGoogle Scholar
  12. 12.
    Sahu KK, Badhala P, Malhotra P, Aggarwal AN (2016) A rare case of rituximab induced interstitial lung disease. Lung India 33(4):472–473Google Scholar
  13. 13.
    Sahu KK, Varma SC (2015) Herpes zoster complicating bortezomib therapy. Indian J Med Res 141(2):247–248Google Scholar

Copyright information

© Indian Society of Hematology and Blood Transfusion 2019

Authors and Affiliations

  1. 1.Department of Internal MedicineSaint Vincent HospitalWorcesterUSA
  2. 2.Division of Pulmonary and Critical Care MedicineMayo ClinicRochesterUSA
  3. 3.Division of Hematology and Medical OncologySaint Vincent Cancer and Wellness CenterWorcesterUSA
  4. 4.University of Massachusetts Medical SchoolWorcesterUSA

Personalised recommendations